Travere Therapeutics (TVTX) Insider Roy Baynes Sells 4,500 Shares

Insider Buying and Selling at Travere Therapeutics, Inc.

Roy Baynes carried out a transaction involving Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 12, 2026, disposing of 4,500 shares. This transaction follows prior portfolio adjustments by the insider, who has also been active in other biotechnology names such as Natera. Insiders buy and sell shares for various personal or tax reasons, and such moves do not inherently point to a negative or positive outlook for the underlying business.

Travere Therapeutics Stock Performance and Valuation

Shares changed hands around $53.80 recently, positioning the company within its broader 52-week band that stretches from a low of $22.06 to a high of $68.73. Travere Therapeutics carries a market capitalization of roughly $5.93 billion and operates with a forward P/E ratio of 11.08 based on future earnings projections. The equity has moved between its 50-day moving average of $61.71 and its 200-day moving average of $43.89 over recent months.

Recent Earnings and Financial Health

The biotechnology company brought in annual revenue of $591.33 million alongside a revenue growth rate of 48.2%. Profitability metrics show a net margin of -7.35% and a return on equity of -2.36%, reflecting ongoing investments in clinical pipelines and rare disease drug development. Investors await the next scheduled earnings report on October 29, 2026, for further updates on financial performance.

Analysts Set New Price Targets

Wall Street firms have kept up a steady stream of updates regarding the biotechnology firm's valuation and market prospects. On September 24, 2026, Guggenheim maintained its buy rating and raised its target to $89.00 from $75.00. Wedbush reiterated an outperform rating with a $76.00 target on September 22, 2026, while HC Wainwright & Co. kept a buy rating and a $67.00 target on the same day. Earlier, Evercore ISI Group maintained an outperform rating and lifted its target to $78.00 from $68.00 on August 10, 2026. Canaccord Genuity maintained a buy rating and moved its target to $70.00 from $62.00 on August 6, 2026, and Wedbush also maintained an outperform rating while adjusting its target to $75.00 from $61.00 that same day. TD Cowen maintained a buy rating with a $75.00 target on August 5, 2026, and Citigroup maintained a buy rating while moving its target to $85.00 from $70.00 on August 5, 2026. Overall, the stock holds a consensus recommendation of strong buy from 14 analysts with a mean price target of $74.21.

Inside the Biotechnology Business

Travere Therapeutics focuses on developing treatments for rare kidney and metabolic conditions. Its key commercial products include therapies targeting rare disorders like IgA nephropathy and cystinuria, alongside clinical-stage pipeline candidates for focal segmental glomerulosclerosis and classical homocystinuria. The firm operates out of San Diego, California, employing a team dedicated to advancing rare disease therapeutics.

What to Watch Next for TVTX

Market participants will continue monitoring future Form 4 filings to track further insider transactions from executives and directors. Additional price target adjustments from covering analysts and the upcoming financial results announcement in late October will provide further clarity on commercial progress.